National immunisation program
Found 6 free book(s)
ATAGI Advice to Immunisation Providers on Use of Bexsero®
www.health.gov.auThe meningococcal C conjugate vaccine has been used in the National Immunisation Program (NIP) since 2003 and has been highly effective in reducing IMD caused by serogroup C meningococci. More information regarding meningococcal disease is available i n Chapter 4.10 of . The Australian
LIVE SHINGLES VACCINE (Zostavax) SCREENING FOR ...
www.health.nsw.gov.auunder the National Immunisation Program. There is also a five year catch -up program for people aged 71 – 79 years until 31 October 2021. Revaccination with Zostavax ® is not recommended for p eople who have rec eived a shingles vaccination at …
Hepatitis B vaccines for Australians - fact sheet
www.tri.edu.auA) All infants, as part of the National Immunisation Program (NIP) B) Children and young adolescents Australian children born since May 2000 would have been eligible for infant hepatitis B vaccination under the NIP. Adolescents about 11–15 years of age (school years 6–8) who had not been previously vaccinated with the
IMMUNISATION
www.moh.gov.sgSingapore national childhood immunisation schedule, 2016 Vaccination against Birth 1 month 3 months 4 months 5 months 6 months 12 months 15 months 18 months 10-11 years^ Tuberculosis BCG Hepatitis B HepB (D1) HepB (D2) HepB (D3)# Diphtheria, tetanus and pertussis DTaP (D1) DTaP (D2) DTaP (D3) DTaP (B1) Tdap (B2) Poliovirus IPV (D1) IPV (D2) IPV ...
N SW Immunisation Schedule
www.health.nsw.gov.auN SW Immunisation Schedule Funded October 2021 Childhood vaccines Age Disease Vaccine Information Birth Hepatitis B H-B-VAX II OR ENGERIX B (IM) Within 7 days of birth (ideally within 24 hours) 6 weeks Diphtheria, tetanus, pertussis, Haemophilus influenzae type b, hepatitis B, polio INFANRIX HEXA (IM) ROTARIX: Dose 1 limited to 6-14 weeks of age
Myocarditis and/or Pericarditis following COVID-19 Vaccines
www.alberta.caThe United Kingdom’s (UK) Joint Committee of Vaccination and Immunisation (JCVI) also reviewed data from the UK, US and Canada and agreed that while there is increasingly robust evidence of an association between vaccination with mRNA COVID-19 vaccines and myocarditis, this is a very rare adverse event.